Identification of Educational Gaps Among Oncologists Who Manage Patients with Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDA) is associated with poor outcomes and presents oncologists with a myriad of clinical challenges. This study was conducted to assess oncologists’ practice patterns and to identify the greatest areas of need for future PDA continuing medical education (CME) programs.
Case vignettes have been validated as an effective tool to assess how physicians approach and treat a wide array of diseases. In order to assess practice patterns for resectable, locally advanced unresectable, and metastatic PDA, an online case vignette survey was distributed to practicing medical oncologists.
Responses from 150 US-practicing oncologists were analyzed, and several key opportunities for future CME programs were identified. For case 1 (patient with resectable PDA), 44% of oncologists did not select an evidence-based adjuvant chemotherapy regimen. For case 2 (patient with locally advanced PDA who develops metastases and neuropathy after first-line nab-paclitaxel/gemcitabine followed by chemoradiation), 57% of oncologists did not select an evidence-based second-line chemotherapy regimen, and 35% selected a regimen containing oxaliplatin, a chemotherapeutic known to cause neuropathy. For case 3 (patient with a pancreatic mass and liver metastases), only 34% of oncologists recommended a biopsy, chest imaging, and liver function tests which should be standard of care assessments with this presentation. For all three cases, clinical trial referral was selected by fewer than 5% of respondents.
This study identified appreciable discrepancies between oncologists’ recommendations and standard evidence-based guidelines. Well-designed CME programs may help to bridge the educational gaps identified and improve adherence to practice guidelines.
KeywordsPancreatic cancer Educational needs assessment Medical oncologist Survey
Source of Funding
This study was financially supported by Celgene Corporation and conducted independently by CE Outcomes. J Emarine and P Merwin are both employees of Celgene and own stock in the corporation.
Compliance with Ethical Standards
Conflicts of Interest
All remaining authors have no conflicts to disclose.
- 4.Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM, et al. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118(9):2338–66. https://doi.org/10.1002/cncr.27514.CrossRefGoogle Scholar
- 7.Worni M, Guller U, White RR, Castleberry AW, Pietrobon R, Cerny T, et al. Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas. 2013;42(7):1157–63. https://doi.org/10.1097/MPA. CrossRefGoogle Scholar
- 11.Abrams RA, Winter KA, Regine WF, Safran H, Hoffman JP, Lustig R, et al. Failure to adhere to protocol specific radiation therapy guidelines was associated with decreased survival in RTOG 9704—a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radait Oncol Biol Phys. 2012;82(2):809–16. https://doi.org/10.1016/j.ijrobp.2010.CrossRefGoogle Scholar
- 13.Laxdal OE, Jennett PA, Wilson TW, Salisbury GM. Improving physician performance by continuing medical education. Can Med Assoc J. 1978;118(9):1051–8.Google Scholar
- 14.Stein LS. The effectiveness of continuing medical education: eight research reports. J Med Educ. 1981;56(2):103–10.Google Scholar
- 15.Davis D, O’Brien MA, Freemantle N, et al. Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? JAMA. 1999;282(9):867–74. https://doi.org/10.1001/jama.282.9.867.CrossRefGoogle Scholar
- 17.Davis D, Bordafe G, Moores LK, et al. Continuing medical education effect on practice performance: effectiveness of continuing medical education: American College of Chest Physicians Evidence-Based Educational Guidelines. Chest. 2009;135(3):42S–8S. https://doi.org/10.1378/chest.08-2517.CrossRefGoogle Scholar
- 18.Accreditation Criteria. Accreditation Council for Continuing Medical Education. http://www.accme.org/requirements/accreditation-requirements-cme-providers/accreditation-criteria. Accessed November 20 2017.
- 20.Peabody JW, Luck J, Glassman P, Jain S, Hansen J, Spell M, et al. Measuring the quality of physician practice by using clinical vignettes: a prospective validation study. Ann Intern Med. 2004;141(10):771–80. https://doi.org/10.7326/0003-4819-141-10-200411160-00008.CrossRefGoogle Scholar
- 21.Luck J, Peabody JW, Lewis BL. An automatic scoring algorithm for computerized clinical vignettes: evaluating physician performance against explicit quality criteria. Int J Med Inform. 2006;75(10–11):710–7.Google Scholar
- 23.Neoptolemos JP, Palmer D, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomized, phase 3 trial. Lancet. 2017;389(10073):1011–24. https://doi.org/10.1016/S0140-6736(16)32409-6.CrossRefGoogle Scholar
- 24.Adam MA, Choudhury K, Dinan MA, Reed SD, Scheri RP, Blazer DG III, et al. Minimally invasive versus open pancreaticoduodenectomy for cancer: practice patterns and short-term outcomes among 7061 patients. Ann Surg. 2015;262(2):372–7. https://doi.org/10.1097/SLA.0000000000001055.CrossRefGoogle Scholar
- 25.Hyder O, Dodson RM, Nathan H, Schneider EB, Weiss MJ, Cameron JL, et al. Influence of patient, physician, and hospital factors on 30-day readmission following pancreatoduodenectomy in the United States. JAMA Surg. 2013;148(12):1095–102. https://doi.org/10.1001/jamasurg.2013.2509.CrossRefGoogle Scholar
- 28.Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(4):1473–81. https://doi.org/10.1001/jama.2013.279201.CrossRefGoogle Scholar